Sonexus Health (Cardinal Health)

Overview

Sonexus Health is Cardinal Health’s specialty patient access and hub services division, operating as Cardinal Health Sonexus Access and Patient Support within the Pharmaceutical and Specialty Solutions segment. Founded independently in 2012 in Lewisville, Texas, Sonexus was acquired by Cardinal Health Specialty Solutions in March 2014. The business combines hub services, a noncommercial specialty pharmacy, and third-party logistics (3PL) to serve specialty pharmaceutical manufacturers launching and managing complex therapies.

As of 2026, Sonexus serves over 1 million patients across its hub programs and has aggressively pivoted toward hybrid and modular service models that accommodate manufacturers who want to insource portions of their patient access operations. The division supports 6 hybrid manufacturers with 60 total programs across three model types. Cardinal Health projects over $50B in Specialty revenues for FY2026 (16% three-year CAGR), with Sonexus hub services as a growth component within that segment.

Important correction for prior references: The original stub incorrectly identified Sonexus as a McKesson subsidiary. McKesson’s comparable hub offering is RxCrossroads by McKesson (now within the Prescription Technology Solutions / CoverMyMeds segment). Sonexus competes directly with Lash Group (Cencora/Lash Group) and McKesson’s hub assets, not alongside them.

Services & Capabilities

Hub Services (Core)

Sonexus provides a comprehensive patient access and support hub for specialty pharmaceutical manufacturers:

• Patient Enrollment & Intake — Multi-channel enrollment (phone, fax, eRx from provider EMR, web portal), automated welcome messaging, HIPAA/TCPA consent management, EHR integration for seamless workflow.
• Benefits Investigation & Prior Authorization — Powered by Benefit Source, Sonexus’s proprietary eBV/ePA platform (PM360 Top Innovation 2019). Connects directly to payers for real-time patient-specific coverage data rather than relying on historical prediction. Payer-specific algorithms reduce unnecessary rejections. Scalable batch processing for annual re-verifications.
• Financial Assistance & Copay Programs — PAPs for uninsured/underinsured ($5.1B+ in free medications dispensed through PAPs in FY2023, 1,650+ PAP shipments per day). Copay assistance enrollment and management. Consumer credit-reporting database access for rapid financial qualification. Foundation assistance navigation.
• Adherence Management — Nurse and case manager outreach via phone, video, chat, and digital channels. Disease education and medication compliance programs. AI/ML tools for patient risk scoring and engagement optimization. Patient portal for refill management.

Noncommercial Specialty Pharmacy

A critical differentiator: Sonexus operates a noncommercial specialty pharmacy that can dispense bridge product while reimbursement is resolved, fulfill prescriptions under manufacturer PAP guidelines, transfer prescriptions to designated specialty pharmacies once coverage is confirmed, and handle first-start programs. This is distinct from Cardinal Health’s broader commercial Specialty Pharmacy Services (70+ outpatient pharmacies across 19 states).

3PL / Specialty Distribution

Sonexus originated partly as a 3PL provider through Sonexus Health Distribution Services, LLC. Capabilities include direct shipment to physician offices, clinics, and hospitals; temperature-controlled specialty logistics; and leverage of Cardinal Health’s distribution network (supplies ~90% of U.S. hospitals, 60,000+ pharmacies). A second distribution center in Houston opened post-acquisition to expand capacity. Sonexus positions itself as an “aggregator of SP networks,” allowing manufacturers to maintain direct distribution control.

REMS Program Support

Sonexus supports specialty drugs requiring REMS compliance through patient registries, certified dispensing via the noncommercial pharmacy, restricted distribution management, and ongoing clinical monitoring aligned with ETASU requirements. Specific REMS program names are not publicly disclosed.

Data & Analytics

• Speech Analytics Platform — Evaluates patient calls for journey mapping and QA
• Quarterly Business Reviews — Translates raw metrics into strategic, patient-focused recommendations
• Real-time Data Visibility — 360-degree product views integrating hub, SP, and distribution data
• Prescriber Behavior Insights — Leverages Cardinal Health’s specialty provider network (5,000+ physicians via Navista Network)
• AI-powered tools — NLP and ML for at-risk patient identification and engagement optimization

Competitive Position

Sonexus is one of the “Big Three” wholesaler-owned hub divisions, competing directly with Cencora/Lash Group and McKesson’s RxCrossroads/CoverMyMeds AMP. Independent competitors include CareMetx, AssistRx, EVERSANA, Valeris (Mercalis + PharmaCord merger, May 2025), and PHIL.

Key differentiators:

• Integrated hub + noncommercial pharmacy + 3PL under one roof, leveraging Cardinal Health’s distribution infrastructure. Few competitors can physically move product through their own distribution and pharmacy while also managing the patient access workflow.
• Hybrid model flexibility — Rather than resisting manufacturer insourcing trends, Sonexus actively supports partial outsourcing models. It offers standalone technology tools (branded eRx, ePA) that bolt onto manufacturer-owned CRMs. This “single service solution model” positions Sonexus to retain relationships even as manufacturers pull functions in-house.
• Benefit Source eBV/ePA platform — Real-time direct payer connectivity for benefits verification and prior authorization is a recognized competitive advantage over competitors relying on historical data or third-party PA tools.
• Cardinal Health data breadth — Access to prescriber behavior data across Cardinal’s specialty provider network, distribution data, and pharmacy data creates intelligence that independent vendors cannot match.

Key vulnerabilities:

• Channel conflict perception — As a wholesaler-owned hub, Sonexus faces the structural concern that Cardinal Health’s distribution interests could influence patient referral flow. While managed through contractual firewalls and program design, this perception drives some manufacturers toward channel-neutral independents.
• No EHR-embedded PA network — McKesson’s CoverMyMeds network (the nation’s largest electronic PA network embedded in EHR workflows) is a significant technology gap Sonexus cannot easily close. McKesson’s planned 2026 launch of combined medical PA + pharmacy PA + enrollment within the EHR could redefine the competitive landscape.
• Rounding error risk — Hub services represent a small fraction of Cardinal Health’s $225B+ revenue, creating potential for underinvestment relative to PE-backed independents that are 100% focused on hub/access.

Market position: Lash Group (Cencora/Lash Group) is likely the largest single hub provider by historical program count. Sonexus competes for the #2-3 position among wholesaler-owned hubs. The global pharma hub and patient access support market was estimated at $3.6B in 2025 (North America ~$1.6B), growing at ~10.8% CAGR.

Recent Developments

• January 2026 — FirstWord Pharma reported several leading manufacturer partners selected Sonexus for hub programs, collectively serving over 1 million patients. Specific manufacturer names undisclosed.
• April 2026 — Sonexus published two-year pulse study of 200 biopharma manufacturers revealing: leadership pressure to insource hub functions increased 10 points from 2024 to 2026; confidence in in-house expertise grew 17 points; nearly half of respondents have considered vendor consolidation.
• March 2025 — Launched AI-powered 24/7 patient chat solution for patient support programs.
• 2025 — Deployed speech analytics platform for patient call analysis and journey mapping.
• 2025 — Internal chatbot deployed to consolidate SOPs and PAP qualification rules, reducing 15-20 minute manual lookups to instant queries.
• 2024-2026 — Strategic pivot to hybrid hub models. Transitioned “one of the largest single-brand hubs in the industry” for a high-volume, multi-indication biologic (name undisclosed). Now supports 6 hybrid manufacturers with 60 programs.
• FY2026 (Cardinal Health) — Specialty revenues projected to exceed $50B (16% three-year CAGR). Q1 FY2026 Pharmaceutical and Specialty Solutions revenue up 23% YoY to $59B.
• 2025 (Cardinal Health) — Navista Network launched for independent oncology providers; $1.1B acquisition strategy pivot toward oncology and urology services (Solaris Health pending).

Client & Partner Ecosystem

Parent company: Cardinal Health — Fortune 15, $225B+ revenue. Sonexus sits within the Pharmaceutical and Specialty Solutions segment.

Sibling entities within Cardinal Health Specialty:

• Specialty Networks / Navista Network (5,000+ oncology/multispecialty physicians)
• Navicor (oncology management services)
• Specialty Pharmacy Services (70+ outpatient pharmacies, 19 states)
• Outcomes (pharmacy engagement and adherence platform)
• Solaris Health (pending acquisition; largest U.S. urology MSO)

Manufacturer clients: Sonexus serves “several leading manufacturer partners” and “top-10 pharma companies” (per ConnectSource launch materials). Specific client names are not publicly disclosed. The transition of “one of the largest single-brand hubs in the industry” suggests a relationship with a major biologic franchise.

Technology partners: Deloitte Digital (ConvergeHEALTH Patient Connect, the foundation for ConnectSource) and Salesforce (CRM backbone). Multiple hub providers including Sonexus and Cencora/Lash Group use Salesforce as CRM infrastructure.

Legal entities (per Oregon regulatory filings, September 2024):

• Sonexus Health, LLC (TX, formed 6/12/2012)
• Sonexus Health Pharmacy Services, LLC (TX, formed 3/25/2013)
• Sonexus Health Distribution Services, LLC (TX, formed 10/28/2011)
• Sonexus Health Financial Solutions, LLC (TX)
• Sonexus Health Access & Patient Support, LLC (TX)

All roll up under Cardinal Health 108, LLC (d/b/a Specialty Pharmaceutical Distribution).

Technology Platform

ConnectSource — Sonexus’s primary CRM and patient engagement platform, introduced October 2017:

• Built as Cardinal Health’s implementation of Deloitte Digital’s ConvergeHEALTH Patient Connect
• Delivered as a Salesforce Managed Package (cloud-based)
• Approximately half of Cardinal Health’s hub clients had migrated to ConnectSource as of 2017, including several top-10 pharma companies
• Integrates with provider and patient portals, manufacturer reporting, and field team platforms
• Supports multi-channel communication: text, email, chat, portal, phone, fax

Benefit Source — Proprietary eBV/ePA platform with direct payer connectivity (PM360 Top Innovation 2019). Key differentiator: real-time patient-specific coverage data vs. competitors using historical data prediction. Payer-specific algorithms built with dose, supply, and formulary knowledge.

AI & Automation:

• 24/7 AI-powered patient chat solution (launched March 2025)
• Speech analytics platform for patient call evaluation and journey mapping
• NLP/ML for patient risk scoring and engagement optimization
• Internal SOP/PAP qualification chatbot

eRx Integration — Providers submit prescriptions through EMR, flowing directly to hub CRM. Available as standalone branded tool for hybrid programs.

Technology positioning note: Sonexus’s differentiation lies in the Deloitte Digital layer (ConnectSource), the proprietary Benefit Source engine, and the speech analytics platform. However, tech-first independent hubs like CareMetx and AssistRx claim more aggressive API-driven architectures and faster time-to-therapy metrics (CareMetx claims 33% faster). The lack of an EHR-embedded PA network comparable to CoverMyMeds is a genuine gap.

Therapeutic Focus

Sonexus serves specialty and complex therapies across multiple disease states. Specific therapeutic area strengths are not granularly disclosed, but the research indicates focus on:

• Oncology — Supported by Cardinal Health’s broader oncology ecosystem (Navista Network, Navicor, Specialty Networks with 5,000+ oncology physicians)
• Rheumatology — Mentioned in context of REMS-mandated therapies served
• Rare diseases — Core hub services use case for limited distribution drugs
• Multi-indication biologics — The transition of “one of the largest single-brand hubs” for a high-volume, multi-indication biologic suggests strength in complex biologic commercialization
• Therapies requiring REMS — Infrastructure aligned with ETASU requirements (patient registries, certified dispensing, restricted distribution)

Cardinal Health’s $1.1B acquisition strategy is pivoting toward oncology and urology services, which may expand Sonexus’s therapeutic reach in these areas.

Analyst Notes

Data quality: The Perplexity research is thorough and well-sourced with inline citations from Cardinal Health newsroom, Drug Channels, Pharmaceutical Commerce, BioXconomy, and regulatory filings. Confidence is rated high.

Critical correction applied: The original stub incorrectly attributed Sonexus to McKesson. This was a significant factual error. McKesson’s hub is RxCrossroads / CoverMyMeds AMP. The competitive framing has been entirely rewritten.

Category reassignment: Changed secondary_categories from ["specialty-pharmacy", "distribution-supply-chain"] to ["specialty-pharmacy", "copay-financial-assistance"]. While Sonexus has 3PL capabilities, these are ancillary to its core identity as a hub + financial assistance + specialty pharmacy platform. The copay/PAP programs ($5.1B+ in free medications, 1,650+ daily PAP shipments) warrant the copay-financial-assistance category.

Revenue opacity: Sonexus revenue is not broken out from Cardinal Health’s segment reporting. The RocketReach ~$12M figure reflects the legacy standalone entity only. Actual hub services revenue is likely significantly larger but buried within a $59B/quarter segment.

Key monitoring items:

• Impact of McKesson’s EHR-embedded specialty access launch (late 2026) on Sonexus competitive position
• Valeris market traction post-Mercalis/PharmaCord merger as a large-scale independent alternative
• Hybrid model adoption rates — Sonexus’s own survey data suggests accelerating manufacturer insourcing pressure
• ConnectSource platform evolution and whether it keeps pace with tech-first independents
• Whether Cardinal Health increases investment in hub services given the 12-14% specialty growth target, or whether Sonexus remains a “rounding error” within the parent’s priorities

Cross-reference gaps: Need to verify whether ConnectiveRx competes directly with Sonexus (ConnectiveRx is more copay/coupon focused) or if the original stub’s competitive framing was inaccurate.

Related concepts: Hub Services Overview, Patient Access Journey, REMS & Limited Distribution